JP2019501224A5 - - Google Patents

Download PDF

Info

Publication number
JP2019501224A5
JP2019501224A5 JP2018554651A JP2018554651A JP2019501224A5 JP 2019501224 A5 JP2019501224 A5 JP 2019501224A5 JP 2018554651 A JP2018554651 A JP 2018554651A JP 2018554651 A JP2018554651 A JP 2018554651A JP 2019501224 A5 JP2019501224 A5 JP 2019501224A5
Authority
JP
Japan
Prior art keywords
carboxylic acid
trifluoromethyl
chromene
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018554651A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501224A (ja
JP6942726B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/012737 external-priority patent/WO2017120591A1/en
Publication of JP2019501224A publication Critical patent/JP2019501224A/ja
Publication of JP2019501224A5 publication Critical patent/JP2019501224A5/ja
Application granted granted Critical
Publication of JP6942726B2 publication Critical patent/JP6942726B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018554651A 2016-01-08 2017-01-09 クロメン化合物および第2活性薬剤の併用薬 Active JP6942726B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662276713P 2016-01-08 2016-01-08
US62/276,713 2016-01-08
US201662277225P 2016-01-11 2016-01-11
US62/277,225 2016-01-11
PCT/US2017/012737 WO2017120591A1 (en) 2016-01-08 2017-01-09 Combination of a chromene compound and a second active agent

Publications (3)

Publication Number Publication Date
JP2019501224A JP2019501224A (ja) 2019-01-17
JP2019501224A5 true JP2019501224A5 (https=) 2020-02-13
JP6942726B2 JP6942726B2 (ja) 2021-09-29

Family

ID=59274050

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018554651A Active JP6942726B2 (ja) 2016-01-08 2017-01-09 クロメン化合物および第2活性薬剤の併用薬

Country Status (8)

Country Link
US (2) US20170196835A1 (https=)
EP (1) EP3400218A4 (https=)
JP (1) JP6942726B2 (https=)
KR (1) KR20180100652A (https=)
CN (1) CN108779091B (https=)
AU (1) AU2017206108B2 (https=)
MX (1) MX388579B (https=)
WO (1) WO2017120591A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017269335B2 (en) 2016-05-26 2021-07-01 Recurium Ip Holdings, Llc EGFR inhibitor compounds
CA3069400A1 (en) * 2017-07-20 2019-01-24 National University Corporation Hokkaido University Combination use of inhibitor targeting pd-1/pd-l1 and cox-2 inhibitor
TR201900059A2 (tr) 2018-01-05 2019-07-22 Gnt Biotech & Medicals Corp Bi̇r farmasöti̇k kombi̇nasyon ve tümör mi̇kroortaminin ve i̇mmünoterapi̇ni̇n regülasyonu i̇çi̇n yöntem
TWI869398B (zh) * 2019-05-10 2025-01-11 英商拜西克爾德有限公司 治療癌症之方法
CN114650815A (zh) * 2019-10-28 2022-06-21 Enzychem生命科学株式会社 癌症治疗的方法及组成物
KR20220100904A (ko) 2019-11-12 2022-07-18 남미 테라퓨틱스, 인크. 암의 치료에 유용한 ido 길항제 전구약물을 함유하는 제제화된 및/또는 공동-제제화된 리포솜 조성물 및 그의 방법
AU2021263914A1 (en) 2020-04-29 2022-11-03 D.E. Shaw Research, Llc PI3K-α inhibitors and methods of use thereof
US20250084048A1 (en) * 2021-10-07 2025-03-13 Relay Therapeutics, Inc. Pi3k-alpha inhibitors and methods of use thereof
KR102889598B1 (ko) * 2023-02-16 2025-11-21 주식회사 재인알앤피 신규한 데커신 유도체, 및 이의 비소세포폐암 예방 또는 치료 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US20040127470A1 (en) 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
US20020103141A1 (en) 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
CA2692973A1 (en) 2007-07-12 2009-01-15 Tragara Pharmaceuticals, Inc. Patient selection and therapeutic methods using markers of prostaglandin metabolism
CN102757417B (zh) 2012-06-18 2014-09-24 中国科学院广州生物医药与健康研究院 氘代苯并吡喃类化合物及其应用
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CN103012350B (zh) 2012-12-07 2015-02-04 中国科学院广州生物医药与健康研究院 苯并吡喃类手性化合物的合成方法
CN103044477B (zh) 2012-12-07 2015-08-05 中国科学院广州生物医药与健康研究院 三甲基硅取代苯并吡喃类化合物及其应用
US9452228B2 (en) 2013-04-01 2016-09-27 Immunomedics, Inc. Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2)
EP2981281B1 (en) * 2013-04-03 2020-07-15 IBC Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
EP3084005A4 (en) 2013-12-17 2017-08-02 Merck Sharp & Dohme Corp. Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
US11034757B2 (en) 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature

Similar Documents

Publication Publication Date Title
JP2019501224A5 (https=)
EP4356973A3 (en) 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer
SA520411982B1 (ar) Kirsten 2 مثبطات نظير الجين الورمي الفيروسي لساركوما جرذ (KRas) واستخدامها لعلاج السرطان
JP2016518437A5 (https=)
SG11201907038WA (en) Quinazoline compound
MY207716A (en) Hiv inhibitor compounds
JP2017105793A5 (https=)
EP4663636A3 (en) Trifluoromethyl substituted pyrazoles as human plasma kallikrein inhibitors
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
JP2016501221A5 (https=)
WO2019035914A8 (en) Macrocyclic mcl-1 inhibitors and methods of use
MX379459B (es) Inhibidores de bromodominios.
JP2013542261A5 (https=)
MX2020001717A (es) Inhibidores macrociclicos de mcl-1 y metodos de uso.
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака
CN108026053A8 (zh) 作为mIDH1抑制剂的稠合的咪唑类化合物
PH12015501836A1 (en) 2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1 -yl)methyl)-3-(2-(trifluoromet hyl)benzyl)quinazolin-4(3h)-one derivatives and their use as phosphoinositide 3-kinase inhibitors
JP2019519533A5 (https=)
JP2019531356A5 (https=)
EA035519B9 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
MX2023009388A (es) Metodos para tratar alteraciones del comportamiento.
MA55084A (fr) Administration d'inhibiteurs de pd-1 pour le traitement du cancer de la peau
JP2017515899A5 (https=)
EP4591940A3 (en) Deoxy- cytidine derivatives for use in cancer therapies
IL287392A (en) New compounds and their pharmaceutical preparations for the treatment of kidney diseases